Bajaj Healthcare Limited

Namrata S. Bajaj Whole Time Director O Self

Driven, dedicated and hard-working leader with over 35+ years

rs,

ents, with a strong focus on procurement and supply chain. He has been with us for the last few years, overseeing the marketing of APIs and Formulations, as well as handling other activities as required

730 MT

ctive Pharmaceutical Ingredient (APIs), Intermediates, Finished Dosage Forms & Nutraceuticals. • 730 MT per month of Active Pharmaceutical Ingredients (APIs) capacity • 94 MT per month Intermediates

94 MT

ms & Nutraceuticals. • 730 MT per month of Active Pharmaceutical Ingredients (APIs) capacity • 94 MT per month Intermediates capacity • 100 Mn pieces per month Finished Dosage Forms capacity • B

250 MT

g Opium Gum and Poppy Straw • Constructed new plant that has capacity to process approximately 250 MT of opium gum and about 2500 MT of Poppy straw • Entered into CDMO Agreement for the supply of 3

2500 MT

Constructed new plant that has capacity to process approximately 250 MT of opium gum and about 2500 MT of Poppy straw • Entered into CDMO Agreement for the supply of 30 new Active Pharmaceutical Ing

24%

th advanced equipments. The facility is expected to be operational by May 2026. 15 Revenue Mix 24% 23% FY24 FY25 76% 77% 36% HYE Sept 25 64% Domestic Exports 11% FY24 17% 16% FY25 H

23%

advanced equipments. The facility is expected to be operational by May 2026. 15 Revenue Mix 24% 23% FY24 FY25 76% 77% 36% HYE Sept 25 64% Domestic Exports 11% FY24 17% 16% FY25 HYE S

76%

ts. The facility is expected to be operational by May 2026. 15 Revenue Mix 24% 23% FY24 FY25 76% 77% 36% HYE Sept 25 64% Domestic Exports 11% FY24 17% 16% FY25 HYE Sept 25 API Form

77%

he facility is expected to be operational by May 2026. 15 Revenue Mix 24% 23% FY24 FY25 76% 77% 36% HYE Sept 25 64% Domestic Exports 11% FY24 17% 16% FY25 HYE Sept 25 API Formulati

36%

cility is expected to be operational by May 2026. 15 Revenue Mix 24% 23% FY24 FY25 76% 77% 36% HYE Sept 25 64% Domestic Exports 11% FY24 17% 16% FY25 HYE Sept 25 API Formulations

64%

to be operational by May 2026. 15 Revenue Mix 24% 23% FY24 FY25 76% 77% 36% HYE Sept 25 64% Domestic Exports 11% FY24 17% 16% FY25 HYE Sept 25 API Formulations 89% 83% 84% 16

11%

2026. 15 Revenue Mix 24% 23% FY24 FY25 76% 77% 36% HYE Sept 25 64% Domestic Exports 11% FY24 17% 16% FY25 HYE Sept 25 API Formulations 89% 83% 84% 16 Financials Profitabilit

“▪ Supply to various Government Institutions across India under tender business ▪ 100 Mn pieces per month Finished Dosage Forms capacity ▪ The Company has entered into a definitive CDMO agreement with esteemed UK/EU based customers for the supply of 30 Active Pharmaceutical Ingredient (APIs) ▪ BHL will undertake the development and supply of these molecules, which will be exclusively manufactured for its clientele.”

“▪ This upcoming centre will accommodate more than 100 research experts working under one roof and will be equipped with advanced equipments.”

“15 Revenue Mix 24% 23% FY24 FY25 76% 77% 36% HYE Sept 25 64% Domestic Exports 11% FY24 17% 16% FY25 HYE Sept 25 API Formulations 89% 83% 84% 16 Financials Profitability Statement Particulars Total Income Gross Contribution EBITDA PBT from Continuing Operations Exceptional Item Tax expense Profit after Taxes & Exceptional item Discontinued Operations Taxation Profit after Tax from discontinued operations Profit for the period FY 2023 FY 2024 FY 2025 Rs in Cr.”

Finished Dosage Forms

1

Company

1

Finished Dosage Forms

Manjusar, Gujarat; Sinnar, Nashik. • 60+ countries BHL has product presence • Europe, USA, Australia, Africa, Middle East, South America, Asian Countries, Australia, New Zealand, Sri Lanka, South East Asia, Russia, Korea etc. • Focus on off – patented APIs Strong R&D Team • Continues investment in top-of- the-line equipment and technology • The Company has initiated various regulatory filings for export of Formulation drugs in ROW Markets. 7 Our Vision and Mission VISION • Our vision is to be a leading pharmaceutical company in India and to become a significant global player by providing high quality and affordable products. • Commitment to continuous improvement and innovation. • To develop environment friendly system. • Contributing towards better healthcare through innovation. MISSION • Innovation and excellence with customer satisfaction. • Our mission at Bajaj Healthcare Limited is to become a significant global player in manufacturing of APIs and Formulations with high standards

Company

Bajaj Healthcare Limited CIN: L99999MH1993PLC072892 Address: 6th Floor, Bhoomi Velocity Infotech Park, Above ICICI Bank, Road No. 23, Wagle Industrial Estate, Thane (W) 400 604 THANK YOU